華森製藥(002907.SZ)收到都樑軟膠囊等12個藥品再註冊批件
格隆匯3月31日丨華森製藥(002907.SZ)公佈，公司於近日收到重慶市藥品監督管理局核准簽發的公司12個產品的“藥品再註冊批件”。產品包括都樑軟膠囊、長鬆(聚乙二醇4000散)、歐得曼(鹽酸特拉唑嗪膠囊)、水王(螺旋藻膠囊)、上清片、卡託普利片、甲硝唑片、西咪替丁膠囊、鹽酸吡硫醇片、氯普噻噸片、氯普噻噸片、曲克蘆丁注射液。
都樑軟膠囊：祛風散寒，活血通絡。用於頭痛屬風寒瘀血阻滯脈絡證者，症見頭脹痛或刺痛，痛有定處，反覆發作，遇風寒誘發或加重。
長鬆(聚乙二醇4000散)：緩解成人便祕的症狀。
歐得曼(鹽酸特拉唑嗪膠囊)：可用於治療良性前列腺增生症。鹽酸特拉唑嗪也可用於治療高血壓，可單獨使用或與其它抗高血壓藥物如利尿劑或β－腎上腺素能阻滯劑合用。
水王(螺旋藻膠囊)：益氣養血，化痰降濁。用於氣血虧虛，痰濁內藴，面色萎黃，頭暈頭昏，四肢倦怠，食慾不振；病後體虛，貧血，營養不良屬上述證候者。
上清片：清熱散風，解毒通便。用於風熱所致頭暈耳鳴，目赤，鼻流黃涕，口舌生瘡，牙齦腫痛，大便祕結。
卡託普利片：用於高血壓，心力衰竭。
甲硝唑片：用於治療腸道和腸外阿米巴病(如阿米巴肝膿腫、胸膜阿米巴病等)。還可用於治療陰道滴蟲病、小袋蟲病和皮膚利什曼病、麥地那龍線蟲感染等。目前還廣泛用於厭氧菌感染的治療。
西咪替丁膠囊：用於緩解胃酸過多引起的胃痛、胃灼熱(燒心)、反酸。
鹽酸吡硫醇片：本品適用於腦外傷後遺症、腦炎及腦膜炎後遺症等的頭暈脹痛、失眠、記憶力減退、注意力不集中、情緒變化的改善；亦用於腦動脈硬化、老年痴呆性精神症狀等。
氯普噻噸片：用於急性和慢性精神分裂症，適用於伴有精神運動性激越、焦慮、抑鬱症狀的精神障礙。
曲克蘆丁注射液：用於缺血性腦血管病(如腦血栓形成、腦栓塞)、血栓性靜脈炎、中心性視網膜炎、血管通透性增高所致水腫等。
上述藥品再註冊批件的取得確保了公司上述藥品的正常生產和銷售，公司將嚴格按照要求開展相應工作，控制產品質量，持續為市場提供高品質的產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
